- Status:
- Red
- Decision Date:
- July 2018
Comments
RED1,2,3,8: NICE TA523 - for untreated acute myeloid leukaemia
RED1,2,3,8: NICE TA728 - for treating advanced systemic mastocytosis (Decision date - Oct 2021)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again